Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares. View CRBP analyst ratings or view top-rated stocks .

What is Corbus Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 1-year price objectives for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $22.00. On average, they predict the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 104.6% from the stock's current price. View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts .

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of 2023. Since then, CRBP shares have increased by 5,429.4% and is now trading at $6.11. View the best growth stocks for 2023 here .

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our CRBP earnings forecast .

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.06) by $0.21.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V) , HP (HPQ) , Fortive (FTV) , Lowe's Companies (LOW) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) , Matinas BioPharma (MTNB) , Inovio Pharmaceuticals (INO) and KushCo (KSHB) .

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen . View institutional ownership trends .

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Corbus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRBP)

$6.11

-0.07 (-1.13%)

(As of 12/5/2023 ET)

Compare

Today's Range: $5.92
▼
$6.25
50-Day Range: $3.16
▼
$6.74
52-Week Range: $2.11
▼
$13.17

Volume: 11,246 shs
Average Volume: 142,398 shs
Market Capitalization: $27.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.50

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 104.6% Upside
$12.50 Price Target
Short Interest: Bearish
1.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 0.17
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($11.00) to ($6.59) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

374th out of 948 stocks

Pharmaceutical Preparations Industry

159th out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.50, Corbus Pharmaceuticals has a forecasted upside of 104.6% from its current price of $6.11.
Amount of Analyst Coverage
Corbus Pharmaceuticals has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.29% of the float of Corbus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Corbus Pharmaceuticals has recently increased by 3.28%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Corbus Pharmaceuticals is -0.65.

2.3

News and Social Media Coverage

News Sentiment
Corbus Pharmaceuticals has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Corbus Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 3 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 16.73% of the stock of Corbus Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($11.00) to ($6.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corbus Pharmaceuticals has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRBP Stock News Headlines

December 1, 2023 | finance.yahoo.com

Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?

December 1, 2023 | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Above 50-Day Moving Average of $5.34

December 5, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 1, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Corbus Pharmaceuticals (NASDAQ:CRBP)

November 29, 2023 | uk.investing.com

Corbus Pharmaceuticals Holding (0SZI)

November 7, 2023 | msn.com

Corbus Pharmaceuticals GAAP EPS of -$2.27 misses by $0.21

November 7, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 7, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 Million

December 5, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 2, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

November 2, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

October 17, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

October 16, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

October 3, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023

September 27, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

September 19, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 13, 2023 | thestreet.com

Corbus Pharmaceuticals (CRBP) Stock Spikes on FDA Fast Track Status Designation

September 10, 2023 | uk.finance.yahoo.com

CRBP - Corbus Pharmaceuticals Holdings, Inc.

August 9, 2023 | msn.com

Oppenheimer Reiterates Corbus Pharmaceuticals Holdings (CRBP) Outperform Recommendation

August 8, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 31, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

June 26, 2023 | seekingalpha.com

Corbus Pharmaceuticals to join Russell Microcap index

June 26, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Set to Join Russell Microcap® Index

May 31, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

May 23, 2023 | fool.com

Corbus Pharmaceuticals (NASDAQ: CRBP)

May 9, 2023 | msn.com

Recap: Corbus Pharmaceuticals Q1 Earnings

May 8, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

See More Headlines

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/05/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRBP
CUSIP: N/A
CIK: 1595097
Web: www.corbuspharma.com
Phone: (617) 963-0100
Fax: 617-663-6085
Employees: 33
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $12.50
High Stock Price Target: $22.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +105.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -320.24%
Return on Assets: -95.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.99
Quick Ratio: 0.99

Sales & Book Value

Annual Sales: $880,000.00
Price / Sales: 30.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.91 per share
Price / Book: 0.77

Miscellaneous

Outstanding Shares: 4,420,000
Free Float: 4,123,000
Market Cap: $26.92 million
Optionable: Optionable
Beta: 2.35

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Yuval Cohen Ph.D. (Age 48)
CEO & Director
Comp: $890.67k
Mr. Sean F. Moran CPA (Age 65)
M.B.A., Chief Financial Officer
Comp: $579.05k
Dr. Rachael Brake Ph.D. (Age 51)
Chief Scientific Officer
Comp: $552.22k
Ted Jenkins
Senior Director of Investor Relations & Corporate Communications
Ms. Lindsey Smith
Head of Corporate Communications & Patient Advocacy
Ms. Christina Bertsch
Head of Human Resources

Key Competitors

View All Competitors

CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings or view top-rated stocks.
What is Corbus Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 1-year price objectives for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $22.00. On average, they predict the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 104.6% from the stock's current price.
View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts.
How have CRBP shares performed in 2023?: Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of 2023. Since then, CRBP shares have increased by 5,429.4% and is now trading at $6.11.
View the best growth stocks for 2023 here.
When is Corbus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CRBP earnings forecast.

How were Corbus Pharmaceuticals' earnings last quarter?: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.06) by $0.21.
What other stocks do shareholders of Corbus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).
Who are Corbus Pharmaceuticals' major shareholders?: Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends.
How do I buy shares of Corbus Pharmaceuticals?: Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial